Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Study Phase : Undisclosed
Sponsor : Partners Group
Deal Size : $1,900.0 million
Deal Type : Acquisition
Partners Group to Acquire Pharmathen, a Leading European Pharmaceutical Company, from BC Partners
Details : On acquisition, Partners Group will work to strengthen Pharmathen’s business in Europe and the US, especially R&D, sustained release’ technologies, including long-acting injectables, slow-releasing oral drugs and ophthalmics segment.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 19, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Highest Development Status : Undisclosed
Sponsor : Partners Group
Deal Size : $1,900.0 million
Deal Type : Acquisition
Lead Product(s) : ADC-based Therapy
Therapeutic Area : Ophthalmology
Study Phase : Undisclosed
Sponsor : Novelty Nobility
Deal Size : Undisclosed
Deal Type : Agreement
GC Biopharma, Novelty Nobility Partner on Geographic Atrophy R&D
Details : Under the agreement terms, GC and Novelty will partner to jointly R&D antibody-based protein therapeutics for geographic atrophy, supporting all stages of the drug development lifecycle.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
October 28, 2024
Lead Product(s) : ADC-based Therapy
Therapeutic Area : Ophthalmology
Highest Development Status : Undisclosed
Sponsor : Novelty Nobility
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Adeno-associated Virus Vector
Therapeutic Area : Ophthalmology
Study Phase : Undisclosed
Sponsor : Astellas Pharma
Deal Size : $962.5 million
Deal Type : Licensing Agreement
Details : Astellas gains rights to utilize the intravitreal retinotropic R100 adeno-associated virus vector invented by 4DMT for one genetic target implicated in rare monogenic ophthalmic diseases, with options to add up to two additional targets implicated for th...
Brand Name : R100
Molecule Type : Large molecule
Upfront Cash : $20.0 million
July 10, 2023
Lead Product(s) : Adeno-associated Virus Vector
Therapeutic Area : Ophthalmology
Highest Development Status : Undisclosed
Sponsor : Astellas Pharma
Deal Size : $962.5 million
Deal Type : Licensing Agreement
Lead Product(s) : AAV-based Gene Therapy
Therapeutic Area : Ophthalmology
Study Phase : Undisclosed
Sponsor : Rentschler Biopharma
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the agreement, Rentschler Biopharma’s ATMP site will support the bioprocess development of AAV material for planned pre-clinical testing of Ikarovec’s novel AAV-based therapy for the treatment of geographic atrophy.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
June 01, 2023
Lead Product(s) : AAV-based Gene Therapy
Therapeutic Area : Ophthalmology
Highest Development Status : Undisclosed
Sponsor : Rentschler Biopharma
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : SLG-100
Therapeutic Area : Ophthalmology
Study Phase : Undisclosed
Sponsor : Grifols International
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Grifols will develop and commercialise immunoglobulin eye drops, SLG-100, for dry eye disease. An immunoglobulin eye drop is a biologic drug that contains naturally occurring functional antibodies generated from human plasma collected from thousands of h...
Brand Name : SLG-100
Molecule Type : Large molecule
Upfront Cash : Undisclosed
March 06, 2023
Lead Product(s) : SLG-100
Therapeutic Area : Ophthalmology
Highest Development Status : Undisclosed
Sponsor : Grifols International
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Study Phase : Undisclosed
Sponsor : Visionary Ventures
Deal Size : $11.9 million
Deal Type : Series A Financing
Re-vana Therapeutics Raises $11.9 Million In Series A Financing
Details : The proceeds will advance the development of Re-Vana’s novel and proprietary photo-crosslinked EyeLief®, EyeLief-SD™ and OcuLief® biodegradable drug delivery technologies and will enable expansion of the company’s operations and development teams...
Brand Name : Undislosed
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
December 06, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Highest Development Status : Undisclosed
Sponsor : Visionary Ventures
Deal Size : $11.9 million
Deal Type : Series A Financing
Lead Product(s) : Regenerative Medicine,Hyaluronic Acid
Therapeutic Area : Ophthalmology
Study Phase : Undisclosed
Sponsor : HTL Biotechnology
Deal Size : Undisclosed
Deal Type : Financing
Details : This investment supports development of the GelMEDIX platform, which enables the delivery of therapeutics from small molecules to cell and gene therapies. HTL will produce methacrylate hyaluronic acid, a key component for specific parameters across the G...